News | June 02, 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company will be holding 26% of the share capital in each of the solar power generating companies.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Analysts expect modest revenue growth but pressure on profitability in the March quarter
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
